ClinicalTrials.gg
CompletedNCT01845649Updated May 9, 2022Results posted

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

A Phase 3 interventional study of WC3011 Estradiol Vaginal Cream and Vehicle in Vulvovaginal Atrophy, sponsored by Warner Chilcott. Completed at 57 sites in United States. Open to female participants aged 35 Years and older. Per ClinicalTrials.gov, last updated 2022-05-09.

Sponsored by Warner Chilcott (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
35 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 56 studies in Dyspareunia with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Dyspareunia · United States.

Enrollment
4th of 53
550 · median 60
Started
2013
with 3 others
Phase 3
13 of 56
none open now
Registered
12th of 56
by date
Lead sponsor
2 of 56
Warner Chilcott

Among the 56 studies in Dyspareunia with a site in United States, this one is the 4th largest by enrollment of the 53 interventional ones that give a count, is one of 4 that started in 2013, is one of 13 in phase 3, and was the 12th registered.

Dyspareunia

159 studies on the registry are indexed under Dyspareunia; 40 are open to participants now.

Browse Dyspareunia studies →

Open to participants now

8 of the 56 studies in Dyspareunia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 28 Dyspareunia studies recruiting now, 11 (39%) set no upper age limit and 14 (50%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 35 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Dyspareunia with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to determine if WC3011 is safe and effective in treating the symptom of painful intercourse secondary to vulvovaginal atrophy as measured by participant self-assessment when compared to vehicle.

03

Conditions studied

  • Vulvovaginal Atrophy

Browse trials for

Keywords

  • Vulvovaginal Atrophy
  • Dyspareunia
  • Postmenopausal
04

Who can participate

Ages eligible
35 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Sexually active with self-identified dyspareunia (pain with sexual activity), at least moderate to severe and most bothersome symptom of vulvovaginal atrophy (VVA)
  • and meets 1 of the following: 12 months spontaneous amenorrhea, 6 months spontaneous amenorrhea with FSH (follicle stimulating hormone) >40 mIU/mL,6 weeks postsurgical bilateral oophorectomy with confirmation by FSH >40 mIU/mL, surgical report or ultrasound, 6 weeks postsurgical hysterectomy with ovary failure confirmed by FSH >40 mIU/mL
  • Age ≥40 years; ≥35 with bilateral oophorectomy
  • Vaginal pH >5.0
  • Less than or equal to 5% superficial cells on vaginal wall cytologic smear
  • Normal clinical breast exam or negative mammogram if ≥ 40 years of age
  • Negative urine pregnancy test (non-hysterectomized and \<12 months amenorrhea)

Exclusion criteria

Exclusion Criteria:

  • Enrollment in Sponsor's Study PR-04409 or PR-05812
  • Participation in clinical trial or use of drug within 30 days prior to screening
  • Known to estrogen and/or progestin therapy
  • Known or suspected premalignant or malignant disease or history -dependent
  • Manifestation or treatment for significant cardiovascular disease (congestive heart failure, stroke or ischemic attack, myocardial infarction, coronary artery bypass, percutaneous angioplasty or >50% angiographic narrowing of coronary artery
  • Thrombophlebitis or thromboembolic disorder or history of
  • Insulin-dependent diabetes mellitus
  • Increased frequency or severity of headaches while on hormone or estrogen therapy
  • Currently taking St. John's Wort
  • Drug/alcohol addiction within past 2 years
  • Treatment with anticoagulants (heparin or warfarin)
  • Smoking ≥15 cigarettes/day
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
550 participants (actual)

Study arms

  • Active comparator
    Vehicle (3 Times/Week)

    Vehicle applied to the vagina daily for 14 days followed by dosing 3 times per week for 10 weeks.

    Drug: Vehicle

  • Experimental
    WC3011 Estradiol Vaginal Cream (3 Times/Week)

    WC3011 Estradiol vaginal cream applied daily for 14 days followed by dosing 3 times per week for 10 weeks.

    Drug: WC3011 Estradiol Vaginal Cream

Interventions

  • Daily for 14 days followed by 3 times per week for 10 weeks

    Also known as: WC3011

  • DrugVehicle

    Daily for 14 days followed by 3 times per week for 10 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment

    Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

    Time frame: Baseline (Day 0) to final assessment (Up to Week 12)

  2. Change From Baseline in Vaginal pH to Final Assessment

    Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

    Time frame: Baseline (Day 0) to final assessment (Up to Week 12)

  3. Change From Baseline in the Percentage of Vaginal Superficial Cells to Final Assessment

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

    Time frame: Baseline (Day 0) to final assessment (Up to Week 12)

  4. Change From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

    Time frame: Baseline (Day 0) to final assessment (Up to Week 12)

Secondary outcomes

  1. Change From Baseline in Participant's Self-Assessment of the Symptom of VVA: Dyspareunia to Weeks 2, 4, 8, and 12

    Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement.

    Time frame: Baseline to Weeks 2, 4, 8 and 12

  2. Change From Baseline in Participant's Self-Assessment of the Other Symptoms of VVA to Weeks 2, 4, 8, 12, and Final Assessment

    Self-Assessment of the symptoms of VVA, other than dyspareunia and vaginal bleeding associated with sexual activity, (vaginal and/or vulvar irritation/itching, dysuria and vaginal dryness) were evaluated by a questionnaire. Each symptom was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores indicate the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

    Time frame: Baseline (Day 0) to Weeks 2, 4, 8, 12, and final assessment (Up to Week 12)

  3. Percentage of Participants With Vaginal Bleeding Associated With Sexual Activity at Each Visit

    Vaginal bleeding associated with sexual activity was assessed by participants as either "present" or "absent". Number of participants with assessment "present" are reported. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

    Time frame: Baseline (Day 0), Weeks 2, 4, 8, 12 and final assessment (Up to Week 12)

  4. Change From Baseline in the Investigator's Assessment of Each of the Signs of VVA to Week 12 and Final Assessment

    Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae each graded on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores are worse. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

    Time frame: Baseline (Day 0) to Week 12 and Final assessment (Up to Week 12)

  5. Change From Baseline in Vaginal pH to Week 12

    Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 12

  6. Change From Baseline in the Percentage of Vaginal Superficial Cells to Week 12

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement.

    Time frame: Baseline to Week 12

  7. Change From Baseline in the Percentage of Vaginal Parabasal Cells to Week 12

    Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement.

    Time frame: Baseline to Week 12

07

Results

Posted May 9, 2022

Participant flow

Participant flow — Overall Study
MilestoneVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Started273277
Safety population271277
Modified intent-to-treat (mitt) population233239
Completed242255
Not completed3122
Withdrew: Adverse event710
Withdrew: Lack of efficacy11
Withdrew: Lost to follow-up22
Withdrew: Withdrew consent124
Withdrew: Protocol deviation74
Withdrew: Reason not specified21

Outcome measures

PrimaryChange From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment

Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

Time frame:
Baseline (Day 0) to final assessment (Up to Week 12)
Reported as:
Mean · score on a scale
Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline2.7 ± 0.442.7 ± 0.45
Change from Baseline to Final Assessment-1.2 ± 0.93-1.5 ± 0.97
PrimaryChange From Baseline in Vaginal pH to Final Assessment

Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

Time frame:
Baseline (Day 0) to final assessment (Up to Week 12)
Reported as:
Mean · score on a scale
Change From Baseline in Vaginal pH to Final Assessment
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline6.35 ± 0.666.37 ± 0.66
Change from Baseline to Final Assessment-0.53 ± 0.92-1.36 ± 0.89
PrimaryChange From Baseline in the Percentage of Vaginal Superficial Cells to Final Assessment

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

Time frame:
Baseline (Day 0) to final assessment (Up to Week 12)
Reported as:
Mean · percentage of superficial cells
Change From Baseline in the Percentage of Vaginal Superficial Cells to Final Assessment
percentage of superficial cellsVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline0.2 ± 0.750.2 ± 0.70
Change from Baseline to Final Assessment1.4 ± 6.0810.1 ± 16.72
PrimaryChange From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

Time frame:
Baseline (Day 0) to final assessment (Up to Week 12)
Reported as:
Mean · percentage of parabasal cells
Change From Baseline in the Percentage of Vaginal Parabasal Cells to Final Assessment
percentage of parabasal cellsVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline50.6 ± 43.0953.5 ± 42.00
Change From Baseline to Final Assessment-14.6 ± 39.55-48.5 ± 45.11
SecondaryChange From Baseline in Participant's Self-Assessment of the Symptom of VVA: Dyspareunia to Weeks 2, 4, 8, and 12

Participant's self-assessment of the symptom of VVA (dyspareunia) was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher score indicates the most bothersome symptoms. A negative change from Baseline indicates improvement.

Time frame:
Baseline to Weeks 2, 4, 8 and 12
Reported as:
Mean · score on a scale
Change From Baseline in Participant's Self-Assessment of the Symptom of VVA: Dyspareunia to Weeks 2, 4, 8, and 12
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline2.7 ± 0.442.7 ± 0.45
Change From Baseline to Week 2-0.8 ± 0.87-0.8 ± 0.89
Change From Baseline to Week 4-1.1 ± 0.93-1.2 ± 0.93
Change From Baseline to Week 8-1.2 ± 0.92-1.5 ± 0.96
Change From Baseline to Week 12-1.2 ± 0.90-1.5 ± 0.95
SecondaryChange From Baseline in Participant's Self-Assessment of the Other Symptoms of VVA to Weeks 2, 4, 8, 12, and Final Assessment

Self-Assessment of the symptoms of VVA, other than dyspareunia and vaginal bleeding associated with sexual activity, (vaginal and/or vulvar irritation/itching, dysuria and vaginal dryness) were evaluated by a questionnaire. Each symptom was scored on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores indicate the most bothersome symptoms. A negative change from Baseline indicates improvement. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

Time frame:
Baseline (Day 0) to Weeks 2, 4, 8, 12, and final assessment (Up to Week 12)
Reported as:
Mean · score on a scale
Change From Baseline in Participant's Self-Assessment of the Other Symptoms of VVA to Weeks 2, 4, 8, 12, and Final Assessment
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Vaginal Itching-Baseline0.9 ± 0.891.0 ± 0.89
Vaginal Itching-Change From Baseline to Week 2-0.3 ± 0.94-0.3 ± 0.94
Vaginal Itching-Change From Baseline to Week 4-0.5 ± 0.94-0.3 ± 0.96
Vaginal Itching-Change From Baseline to Week 8-0.5 ± 0.98-0.4 ± 0.97
Vaginal Itching-Change From Baseline to Week 12-0.6 ± 0.95-0.4 ± 0.96
Vaginal Itching-Change From Baseline to Final Assessment-0.5 ± 0.98-0.4 ± 0.95
Dysuria-Baseline0.4 ± 0.740.4 ± 0.72
Dysuria-Change From Baseline to Week 2-0.1 ± 0.82-0.1 ± 0.77
Dysuria-Change From Baseline to Week 4-0.2 ± 0.76-0.1 ± 0.80
Dysuria-Change From Baseline to Week 8-0.2 ± 0.73-0.2 ± 0.76
Dysuria-Change From Baseline to Week 12-0.2 ± 0.78-0.2 ± 0.75
Dysuria-Change From Baseline to Final Assessment-0.2 ± 0.80-0.2 ± 0.72
Vaginal Dryness-Baseline2.3 ± 0.802.3 ± 0.73
Vaginal Dryness-Change From Baseline to Week 2-0.6 ± 1.08-0.7 ± 1.00
Vaginal Dryness-Change From Baseline to Week 4-0.8 ± 0.96-0.9 ± 0.91
Vaginal Dryness-Change From Baseline to Week 8-0.9 ± 0.98-1.1 ± 0.91
Vaginal Dryness-Change From Baseline to Week 12-0.9 ± 0.98-1.2 ± 0.94
Vaginal Dryness-Change From Baseline to Final Assessment-0.8 ± 0.98-1.2 ± 0.97
SecondaryPercentage of Participants With Vaginal Bleeding Associated With Sexual Activity at Each Visit

Vaginal bleeding associated with sexual activity was assessed by participants as either "present" or "absent". Number of participants with assessment "present" are reported. Final Assessment is defined as the last available post-baseline assessment for the given efficacy endpoint.

Time frame:
Baseline (Day 0), Weeks 2, 4, 8, 12 and final assessment (Up to Week 12)
Reported as:
Number · percentage of participants
Percentage of Participants With Vaginal Bleeding Associated With Sexual Activity at Each Visit
percentage of participantsVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline27.028.0
Week 215.916.4
Week 47.97.2
Week 810.86.7
Week 1212.17.5
Final Assessment14.46.5
SecondaryChange From Baseline in the Investigator's Assessment of Each of the Signs of VVA to Week 12 and Final Assessment

Investigator's assessment of vaginal health was performed by visual inspection of the vagina with respect to the signs of VVA: atrophy, pallor, vaginal dryness, friability, and petechiae each graded on a 4-point scale where: 0=none, 1=mild, 2=moderate or 3=severe. Higher scores are worse. A negative change from Baseline indicates improvement. Final assessment is defined as the last available postbaseline assessment.

Time frame:
Baseline (Day 0) to Week 12 and Final assessment (Up to Week 12)
Reported as:
Mean · score on a scale
Change From Baseline in the Investigator's Assessment of Each of the Signs of VVA to Week 12 and Final Assessment
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Atrophy-Baseline2.0 ± 0.602.0 ± 0.64
Atrophy-Change From Baseline to Week 12-0.5 ± 0.75-0.9 ± 0.84
Atrophy-Change From Baseline to Final Assessment-0.5 ± 0.75-0.9 ± 0.83
Pallor-Baseline1.8 ± 0.691.8 ± 0.70
Pallor-Change From Baseline to Week 12-0.6 ± 0.75-0.9 ± 0.84
Pallor-Change From Baseline to Final Assessment-0.6 ± 0.75-0.9 ± 0.85
Dryness-Baseline1.8 ± 0.681.8 ± 0.75
Dryness-Change From Baseline to Week 12-0.5 ± 0.85-0.9 ± 0.94
Dryness-Change From Baseline to Final Assessment-0.5 ± 0.83-0.9 ± 0.95
Friability-Baseline1.1 ± 0.931.2 ± 0.99
Friability-Change From Baseline to Week 12-0.6 ± 0.95-1.0 ± 0.99
Friability-Change From Baseline to Final Assessment-0.6 ± 0.95-1.0 ± 0.97
Petechiae-Baseline0.7 ± 0.830.8 ± 0.89
Petechiae-Change From Baseline to Week 12-0.3 ± 0.78-0.6 ± 0.86
Petechiae-Change From Baseline to Final Assessment-0.3 ± 0.78-0.6 ± 0.85
SecondaryChange From Baseline in Vaginal pH to Week 12

Vaginal pH was obtained at baseline and final visit of the study. The pH was a numeric value from 0 to 14 expressing the acidity or alkalinity of the vaginal fluids where 7 was neutral, lower values were more acidic (values of 0-6) and higher values more alkaline (values of 8-14). A negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Vaginal pH to Week 12
score on a scaleVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline6.35 ± 0.666.37 ± 0.66
Change From Baseline to Week 12-0.53 ± 0.93-1.35 ± 0.89
SecondaryChange From Baseline in the Percentage of Vaginal Superficial Cells to Week 12

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of superficial cells. A positive change from Baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of superficial cells
Change From Baseline in the Percentage of Vaginal Superficial Cells to Week 12
percentage of superficial cellsVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline0.2 ± 0.750.2 ± 0.70
Change From Baseline to Week 121.2 ± 5.3510.5 ± 17.19
SecondaryChange From Baseline in the Percentage of Vaginal Parabasal Cells to Week 12

Vaginal wall smears were collected from each participant. The smears were sent to the central laboratory for analysis to determine the percentage of parabasal cells. A negative change from Baseline indicates improvement.

Time frame:
Baseline to Week 12
Reported as:
Mean · percentage of parabasal cells
Change From Baseline in the Percentage of Vaginal Parabasal Cells to Week 12
percentage of parabasal cellsVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Baseline50.6 ± 43.0953.5 ± 42.00
Change From Baseline to Week 12-14.9 ± 39.88-48.2 ± 45.65

Adverse events

Collected over Up to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle (3 Times/Week)0/271 (0%)1/271 (0.4%)42/271 (15.5%)
WC3011 Estradiol Vaginal Cream (3 Times/Week)0/277 (0%)3/277 (1.1%)38/277 (13.7%)
Most frequent serious events
Most frequent serious events
EventVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Atrial FibrillationCardiac disorders1/2710/277
AppendicitisInfections and infestations0/2711/277
Accidental OverdoseInjury, poisoning and procedural complications0/2711/277
Brain NeoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2711/277
Deep vein thrombosisVascular disorders0/2711/277
Most frequent other events
Most frequent other events
EventVehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)
Urinary tract infectionInfections and infestations21/27110/277
Vulvovaginal mycotic infectionInfections and infestations9/27119/277
Application site painGeneral disorders15/2719/277

Baseline characteristics

Safety Population included participants who were randomized into the study and took at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Vehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)Total
Mean58.6 ± 6.158.7 ± 6.458.6 ± 6.3
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle (3 Times/Week)WC3011 Estradiol Vaginal Cream (3 Times/Week)Total
Female271277548
Male000
08

Study locations

57 sites
  • Warner Chilcott Investigational Study Site
    Birmingham, Alabama 35211, United States
  • Warner Chilcott Investigational Study Site
    Mobile, Alabama 36608, United States
  • Warner Chilcott Investigational Study Site
    Chandler, Arizona 85224, United States
  • Warner Chilcott Investigational Study Site
    Phoenix, Arizona 85032, United States
  • Warner Chilcott Investigational Study Site
    Scottsdale, Arizona 85251, United States
  • Warner Chilcott Investigational Study Site
    Tucson, Arizona 85710, United States
  • Warner Chilcott Investigational Study Site
    Tucson, Arizona 85712, United States
  • Warner Chilcott Investigational Study Site
    Sacramento, California 95821, United States
  • Warner Chilcott Investigational Study Site
    San Diego, California 92103, United States
  • Warner Chilcott Investigational Study Site
    San Diego, California 92108, United States
  • Warner Chilcott Investigational Study Site
    San Diego, California 92123, United States
  • Warner Chilcott Investigational Study Site
    New London, Connecticut 06320, United States
  • Warner Chilcott Investigational Study Site
    Washington, District of Columbia 20036, United States
  • Warner Chilcott Investigational Study Site
    Boynton Beach, Florida 33472, United States
  • Warner Chilcott Investigational Study Site
    Clearwater, Florida 33759, United States
  • Warner Chilcott Investigational Study Site
    Jacksonville, Florida 32216, United States
  • Warner Chilcott Investigational Study Site
    Miami, Florida 33186, United States
  • Warner Chilcott Investigational Study Site
    Ormond Beach, Florida 32174, United States
  • Warner Chilcott Investigational Study Site
    Palm Beach Gardens, Florida 33410, United States
  • Warner Chilcott Investigational Study Site
    Pinellas Park, Florida 33781, United States
  • Warner Chilcott Investigational Study Site
    West Palm Beach, Florida 33409, United States
  • Warner Chilcott Investigational Study Site
    Atlanta, Georgia 30342, United States
  • Warner Chilcott Investigational Study Site
    Roswell, Georgia 30075, United States
  • Warner Chilcott Investigational Study Site
    Savannah, Georgia 31406, United States
  • Warner Chilcott Investigational Study Site
    Granger, Indiana 46530, United States
  • Warner Chilcott Investigational Study Site
    Lexington, Kentucky 40509, United States
  • Warner Chilcott Investigational Study Site
    Marrero, Louisiana 70072, United States
  • Warner Chilcott Investigational Study Site
    New Orleans, Louisiana 70115, United States
  • Warner Chilcott Investigational Study Site
    Kalamazoo, Michigan 49009, United States
  • Warner Chilcott Investigational Study Site
    Chaska, Minnesota 55318, United States
  • Warner Chilcott Investigational Study Site
    Las Vegas, Nevada 89113, United States
  • Warner Chilcott Investigational Study Site
    Las Vegas, Nevada 89128, United States
  • Warner Chilcott Investigational Study Site
    Moorestown, New Jersey 08057, United States
  • Warner Chilcott Investigational Study Site
    Greensboro, North Carolina 27408, United States
  • Warner Chilcott Investigational Study Site
    New Bern, North Carolina 28562, United States
  • Warner Chilcott Investigational Study Site
    Raleigh, North Carolina 27607, United States
  • Warner Chilcott Investigational Study Site
    Winston-Salem, North Carolina 27103, United States
  • Warner Chilcott Investigational Study Site
    Cincinnati, Ohio 45249, United States
  • Warner Chilcott Investigational Study Site
    Cleveland, Ohio 44122, United States
  • Warner Chilcott Investigational Study Site
    Columbus, Ohio 43213, United States
  • Warner Chilcott Investigational Study Site
    Jenkintown, Pennsylvania 19046, United States
  • Warner Chilcott Investigational Study Site
    Philadelphia, Pennsylvania 19114, United States
  • Warner Chilcott Investigational Study Site
    Pittsburgh, Pennsylvania 15206, United States
  • Warner Chilcott Investigational Study Site
    Warwick, Rhode Island 02886, United States
  • Warner Chilcott Investigational Study Site
    Bluffton, South Carolina 29910, United States
  • Warner Chilcott Investigational Study Site
    Greer, South Carolina 29650, United States
  • Warner Chilcott Investigational Study Site
    Austin, Texas 78759, United States
  • Warner Chilcott Investigational Study Site
    Dallas, Texas 75230, United States
  • Warner Chilcott Investigational Study Site
    Dallas, Texas 75231, United States
  • Warner Chilcott Investigational Study Site
    Dallas, Texas 75234, United States
  • Warner Chilcott Investigational Study Site
    Houston, Texas 77030, United States
  • Warner Chilcott Investigational Study Site
    San Antonio, Texas 78229, United States
  • Warner Chilcott Investigational Study Site
    South Jordan, Utah 84095, United States
  • Warner Chilcott Investigational Study Site
    Norfolk, Virginia 23507-1627, United States
  • Warner Chilcott Investigational Study Site
    Richmond, Virginia 23233, United States
  • Warner Chilcott Investigational Study Site
    Seattle, Washington 98105, United States
  • Warner Chilcott Investigational Study Site
    Spokane, Washington 99207, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2013 to primary completion in Nov 2013, 7 months.

Results were first posted in May 2022, 8 years 5 months after primary completion. A results delay was requested in Feb 2015.

Of 10 phase 3 interventional studies under Dyspareunia, half reached primary completion within 13 months of starting (the median); a quarter within 5 and three quarters within 28. This study's 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2013
First posted
May 3, 2013
StartActual
Apr 12, 2013
Primary completionActual
Nov 20, 2013
CompletionActual
Nov 20, 2013
Results delay requested
Feb 24, 2015
Results first posted
May 9, 2022
Last update
May 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01845649
Lead sponsor
Warner Chilcott
Responsible party
Sponsor
First posted
May 3, 2013
Start date
Apr 12, 2013
Primary completion
Nov 20, 2013
Completion
Nov 20, 2013
Results posted
May 9, 2022
Last update
May 9, 2022

Study contacts

Anna Chan, PharmD
study director · Warner Chilcott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion